The good news for Biostage(BSTG) shareholders is that the company is not quite dead yet. With cash set to run out in the second quarter and several quarters away from early stage clinical trials for its esophageal implant , Biostage stock has been swiftly moving downward. From over $2 per share last May, to over $0.70 at Wednesday’s… Read More »
Harvard Bioscience (HBIO) recently completed the spinoff of its regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technologies (HART). As we previously noted, the parent’s CEO and other top management moved to the spinco, creating a leadership void. The posts have since been filled and the company recently announced the details of some further ‘inducement grants’ for its new management team. Here… Read More »
Last Friday, a spinoff we’ve written about several times became a reality. Harvard Biosciences (HBIO) spun off Harvard Apparatus Regenerative Technologies(HART) to shareholders. HBIO shareholders received one share of HART for every four shares of HBIO owned. With management going to the spin off, recently appointed HBIO CEO Jeffery A. Duchemin received the additional titles of President and… Read More »
Harvard Bioscience Inc’s (HBIO) board of directors approved the spinoff of its regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology. The spin is set to take place on November 1st with HBIO shareholders receiving 1 share of the new company for every 4 shares of HBIO owned. The new company will trade under the ticker ‘HART’ and a when… Read More »
What does it take to get into Harvard? Around $4, plus commission. Massachusetts-based Harvard Bioscience(HBIO) has long been a leading manufacturer of apparatus and scientific equipment, but, with a market capitalization of just $115 million, it has flown under the radar of many investors. Founded in the basement of Harvard Medical School in 1901 by Dr. William T.… Read More »